Clinical experience with a low-dose fixed combination of perindopril plus indapamide in a primary-care setting: The PRETEND study

Therapy

Volumn 4, Issue 5, 2007, Pages 677-683

  Barrios, Vivencio ^a   Escobar, Carlos ^a   Divison, Juan Antonio ^a   Medialdea, Francisco ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antihypertensive therapy; Hypertension; Indapamide; Perindopril; Perindoril plus indapamide; Primary care

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; PERINDOPRIL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

EID: 35348918311     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.5.677     Document Type: Article

References (36)

1. McMahon S, Peto R, Cutler J et al.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765-774 (1990).
2. Chobanian AV, Bakris GL, Black HR et al.; National High Blood Pressure Education Program Co-ordinating Committee: the seventh report of the Joint National Committee: on prevention, detection, evaluation, an treatment of high blood pressure. JAMA 289, 2560-2572 (2003).
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
4. Wang YR, Alexander GC, Stafford RS: Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch. Intern. Med. 167, 141-147 (2007).
5. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49, 69-75 (2007).
6. Primatesta P, Poulter NR: Improvement in hypertension management in England: results from the Health Survey for England 2003. J. Hypertens. 24, 1187-1192 (2006).
7. Roca B, Suarez C, Ceballos A, Varela JM et al.: Control of hypertension in patients at high risk of cardiovascular disease. QJM98, 581-588 (2005).
8. Rodriguez GC, Artigao LM, Llisterri JL et al.: Control of hypertension in elderly patients receiving primary care in Spain. Rev. Esp. Cardiol. 58, 359-366 (2005).
9. Morgan TO, Anderson AIE, Macinnis RJ: Ace inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 14, 241-247 (2001).
10. Motwani JG: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J. Renin Angiotensin Aldosterone Syst. 3, 72-78 (2002).
11. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62, 44-62 (2002).
12. Mourad JJ, Waeber B, Zannad F et al.: Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/indapamide versus a sequential monotherapy or stepped-care approach. J. Hypertens. 12, 2379-2386 (2004).
13. Morgan T, Anderson A: A low-dose combination therapy with perindopril and indapamide compared with irbesartan. Clin. Drug Investig. 22, 553-560 (2002).
14. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000).
15. Rosser WW: Application of evidence from randomised controlled trials to general practice. Lancet 353, 661-664 (1999).
16. Steg PG, Lopez-Sendon J, Lopez de Sa E et al.: External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med. 167, 68-73 (2007).
17. Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderón A: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile. The LAURA study. Int. J. Clin. Pract. 60, 1364-1370 (2006).
18. Barrios V, Navarro A, Esteras A et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Blood Press. 11, 95-100 (2002).
19. Cifkova R, Erdine S, Fagard R et al.: Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J. Hypertens. 21, 1779-1786 (2003).
20. Dahlof B, Gosse P, Gueret P et al.: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens. 23, 2063-2070 (2005).
21. Mogensen CE, Viberti G, Halimi S et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Hypertension 41, 1063-1071 (2003).
22. Mallion JM, Chamontin B, Asmar R et al.: Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am. J. Hypertens. 17, 245-251 (2004).
23. de Luca N, Mallion JM, O'Rourke MF et al.: Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first-line combination: the REASON echocardiography study. Am. J. Hypertens. 17, 660-667 (2004).
24. Asmar RG, London GM, O'Rourke ME et al.: Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J. Hypertens. 19(Suppl.). S15-S20 (2001).
25. Laurent S: Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage. J. Hypertens. 21 (Suppl.), S11-18 (2003).
26. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME: Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J. Hypertens. 22, 1623-1630 (2004).
27. Safar ME, Myers MG, Leenen F, Asmar R: Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. J. Hypertens. 20, 1653-1661 (2002).
28. London GM, Asmar RG, O'Rourke MF, Safar ME: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J. Am. Coll. Cardiol. 43, 92-99 (2004).
29. Myers MG, Asmar R, Leenen FH, Safar M: Fixed low-dose combination therapy in hypertension - a dose response study of perindopril and indapamide. J. Hypertens. 18, 317-325 (2000).
30. Myers MG, Leenen FH: The Impact of one or two missed doses on the duration of action of combined perindopril and indapamide. J. Hum. Hypertens. 21, 86-93 (2007).
31. Barrios V, Escobar C, Llisterri JL et al.: Blood pressure and lipid control and coronary risk in the hypertensive population attended in primary care setting in Spain. The PRESCOT study. Rev. Clin. Esp. 207(4), 172-178 (2007).
32. Hosie J, Wilklund I: Managing hypertension in general practice: can do we better? J. Hum. Hypertens. 9, S15-S18 (1995).
33. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A: Blood pressure control in the hypertensive population. Lancet 349, 454-457 (1997).
34. Blood Pressure Lowering Treatment Trialist Collaboration: Effects of ACE inhibitors, calcium channel blockers, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356, 1955-1964 (2000).
35. Marques E, Gil V, Casado, JJ et al.: Analysis of studies published on therapy non-compliance with hypertension treatment in Spain between 1984 and 2005. Aten. Primaria 38, 325-332 (2006).
36. Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370(9590), 829-840 (2007).